Clinical trial
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With…
NCT00299546 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00299546 |
|---|---|
| Title | A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s) |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s) |
| Lead sponsor | Centocor, Inc., Industry |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Biological, Drug |
| Interventions | Placebo, Golimumab 50 mg, Golimumab 100 mg |
| Enrollment | 461 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | May 1, 2012 |
| First posted | Mar 7, 2006 |
| Last update posted | Feb 27, 2014 |
| Countries | Australia, Austria, Canada, Finland, Germany, Netherlands, New Zealand, Spain, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: